Thus, Tctex1 may be a potential target in GBM, and patients with high tumor levels of Tctex1 might benefit from individualized therapeutic approaches involving the cannabinoids–cannabinoid receptors axis. This evidence concerns the gene DYNLT1 and glioblastoma.